{"id":304996,"date":"2026-10-13T12:02:14","date_gmt":"2026-10-13T06:32:14","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=304996"},"modified":"2026-10-13T12:02:14","modified_gmt":"2026-10-13T06:32:14","slug":"pharma-brand-medical-device-and-diagnostic-chain-stocks-next-phase-spotlight","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/pharma-brand-medical-device-and-diagnostic-chain-stocks-next-phase-spotlight\/","title":{"rendered":"3 Pharma Brand, Medical Device and Diagnostic Chain Stocks With a Strong Future Roadmap: Mankind Pharma, Poly Medicure and Suraksha Diagnostic"},"content":{"rendered":"

Mankind Pharma Rs 2,400.00, P\/E 47.91. Poly Medicure Rs 1,641.20, P\/E 51.87. Suraksha Diagnostic Rs 308.60, P\/E 46.05. Closing prices of 12 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Pharma brand, medical device and diagnostic chain stocks with the clearest long-term roadmaps today include Mankind Pharma in branded formulations across chronic and acute therapies, Poly Medicure in infusion sets, needles, catheters and dialysis products and Suraksha Diagnostic in diagnostic and pathology testing through labs and collection centres. FY26 revenue growth was 14.8% at Mankind Pharma, 13.4% at Poly Medicure and 22.5% at Suraksha Diagnostic. P\/E stands at 47.91 for Mankind Pharma (industry 37.59), 51.87 for Poly Medicure (industry 62.79) and 46.05 for Suraksha Diagnostic (industry 62.79). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.<\/p>\n<\/p><\/div>\n

Pharma brand, medical device and diagnostic chain stocks give investors exposure to medicines, devices and tests that patients, hospitals and doctors rely on. Prescription growth, export orders and test volumes decide how much of that demand turns into profit.<\/p>\n

This list covers three pharma brand, medical device and diagnostic chain stocks: Mankind Pharma for branded formulations across chronic and acute therapies, Poly Medicure for infusion sets, needles, catheters and dialysis products and Suraksha Diagnostic for diagnostic and pathology testing through labs and collection centres. Every figure comes from the latest reported financials and the 12 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n